233 related articles for article (PubMed ID: 25223386)
1. Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone.
Zheng Y; Basel D; Chow SO; Fong-Yee C; Kim S; Buttgereit F; Dunstan CR; Zhou H; Seibel MJ
Clin Exp Metastasis; 2014 Dec; 31(8):921-33. PubMed ID: 25223386
[TBL] [Abstract][Full Text] [Related]
2. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
Zheng Y; Chow SO; Boernert K; Basel D; Mikuscheva A; Kim S; Fong-Yee C; Trivedi T; Buttgereit F; Sutherland RL; Dunstan CR; Zhou H; Seibel MJ
J Bone Miner Res; 2014 Sep; 29(9):1938-49. PubMed ID: 24676805
[TBL] [Abstract][Full Text] [Related]
3. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
4. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
5. Expression of RANK-ligand in prostate cancer cell lines.
Penno H; Nilsson O; Brändström H; Winqvist O; Ljunggren O
Scand J Clin Lab Invest; 2009; 69(1):151-5. PubMed ID: 19058084
[TBL] [Abstract][Full Text] [Related]
6. RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway.
Park M; Cho YJ; Kim B; Ko YJ; Jang Y; Moon YH; Hyun H; Lim W
Sci Rep; 2021 Jun; 11(1):12186. PubMed ID: 34108600
[TBL] [Abstract][Full Text] [Related]
7. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
8. Prostatic Acid Phosphatase Alters the RANKL/OPG System and Induces Osteoblastic Prostate Cancer Bone Metastases.
Kirschenbaum A; Izadmehr S; Yao S; O'Connor-Chapman KL; Huang A; Gregoriades EM; Yakar S; Levine AC
Endocrinology; 2016 Dec; 157(12):4526-4533. PubMed ID: 27783536
[TBL] [Abstract][Full Text] [Related]
9. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.
Hashizume M; Hayakawa N; Mihara M
Rheumatology (Oxford); 2008 Nov; 47(11):1635-40. PubMed ID: 18786965
[TBL] [Abstract][Full Text] [Related]
10. Effects of the Bone/Bone Marrow Microenvironments on Prostate Cancer Cells and CD59 Expression.
Yan B; Li Y; Min S; Zhang P; Xu B; Wang Z; Zhang W; Chen J; Luo G; Liu C
Biomed Res Int; 2020; 2020():2753414. PubMed ID: 32337233
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
13. CCN3 promotes prostate cancer bone metastasis by modulating the tumor-bone microenvironment through RANKL-dependent pathway.
Chen PC; Cheng HC; Tang CH
Carcinogenesis; 2013 Jul; 34(7):1669-79. PubMed ID: 23536580
[TBL] [Abstract][Full Text] [Related]
14. RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro.
Casimiro S; Mohammad KS; Pires R; Tato-Costa J; Alho I; Teixeira R; Carvalho A; Ribeiro S; Lipton A; Guise TA; Costa L
PLoS One; 2013; 8(5):e63153. PubMed ID: 23696795
[TBL] [Abstract][Full Text] [Related]
15. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.
Lu Y; Cai Z; Xiao G; Keller ET; Mizokami A; Yao Z; Roodman GD; Zhang J
Cancer Res; 2007 Apr; 67(8):3646-53. PubMed ID: 17440076
[TBL] [Abstract][Full Text] [Related]
16. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization.
Chu GC; Zhau HE; Wang R; Rogatko A; Feng X; Zayzafoon M; Liu Y; Farach-Carson MC; You S; Kim J; Freeman MR; Chung LW
Endocr Relat Cancer; 2014 Apr; 21(2):311-26. PubMed ID: 24478054
[TBL] [Abstract][Full Text] [Related]
17. Abrogation of prostaglandin E-EP4 signaling in osteoblasts prevents the bone destruction induced by human prostate cancer metastases.
Watanabe K; Tominari T; Hirata M; Matsumoto C; Maruyama T; Murphy G; Nagase H; Miyaura C; Inada M
Biochem Biophys Res Commun; 2016 Sep; 478(1):154-161. PubMed ID: 27450806
[TBL] [Abstract][Full Text] [Related]
18. Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling.
Jin F; Qu X; Fan Q; Wang L; Tang T; Hao Y; Dai K
Mol Med Rep; 2013 Nov; 8(5):1486-92. PubMed ID: 24064566
[TBL] [Abstract][Full Text] [Related]
19. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
[TBL] [Abstract][Full Text] [Related]
20. Ablation of p38α MAPK Signaling in Osteoblast Lineage Cells Protects Mice From Bone Loss Induced by Estrogen Deficiency.
Thouverey C; Caverzasio J
Endocrinology; 2015 Dec; 156(12):4377-87. PubMed ID: 26441240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]